Pain is a pain to research.
In the early 2000s, a small biotech company had a big idea: blocking nerve growth factor, a protein made in response to pain.
Jianguo Cheng, a Cleveland Clinic pain specialist and science chief for the American Academy of Pain Medicine.
There's a good chance of preventing brain responses that lead to chronic pain if patients can get through that "initially very rough period," said Dr.
She is studying cannabinoid receptors in the brain, looking at how pain affects one type but not another.